Kornimate/medical-research-clean huggingface dataset:
self-esteem status among medical students: a descriptive study

Conditions: Self-esteem Among Medical Students

Summary: the goal of this observational study is to assess the status of self-esteem in medical students of a medical college, focusing on different academic years, and various sociodemographic factors. the main questions it aims to answer are: what is the prevalence of low, normal, and high self-esteem among medical students? how do sociodemographic factors (age, gender, nationality, scholarship status, religion, academic year, education level of parents, occupation of parents, motivation behind choosing medicine as a career) influence self-esteem in medical students? since this is an observational study, there is no formal comparison group. researchers will explore the variations in self-esteem levels based on sociodemographic characteristics. participants will complete a semi-structured questionnaire providing demographic details, such as age, gender, academic year, and parental education/occupation, and answering the rosenberg self-esteem scale.

self-esteem is the assessment and experience related to self-value, the insight of self-ability as well as the reception of the whole self. abraham maslow involved self-esteem in his "hierarchy of human needs" which he depicted it in two forms - the need for respect from others (in the form of recognition, success, and admiration), and the need for self-respect (in the form of self-love, self-confidence, skill, or aptitude). despite being a predictor of high academic achievement and overall happiness, very few studies are done in medical students of nepal. this study aims to assess the status of self-esteem in medical students and compare the prevalence of low, normal and high self-esteem among medical students of different academic years. for this study, rosenberg self-esteem scale tool is being used. to obtain the data for the study, convenience sampling technique will be used. research is conducted among medical students of kathmandu medical college and teaching hospital, from 20th august to 10th september. the sample size is calculated as 227. the data will be collected via a semi-structured questionnaire in the english language via google forms. spss version 26.0 will be used to analyse the data.

Eligibility criteria:
inclusion criteria: * aged 18 years or older * medical students from first year to final year studying bachelor in medicine and bachelor in surgery at kathmandu medical college and teaching hospital * willing to participate in the study and provide informed consent. exclusion criteria: * student studying bachelor of dental surgery and paramedical studies * those who do not fill up the form completely * those who are interns and already graduated from medical college * those who do not give consent

Keywords: medical students mental health prevalence self concept self-esteem
development of a clinical screening, diagnostic and evaluation tool for patients with lower limb lymphedema: aim 3

Conditions: Lower Limb Lymphedema

Summary: the current best practice is a three-stage classification consensus guideline as published by the international society of lymphology (isl). severity of lymphedema is however not only determined by presence of pitting (which is the phenomenon when the swollen area has a dimple (or pit) after you press it for 5 to 10 seconds) and presence of adipose tissue or not, but is also determined by the volume of the edema, a quantification of the condition of the skin and the location/expansion of the edema over the body. currently a severity score considering these different aspects does not exist. although there is consensus that the isl staging systems is a necessary part of the diagnosis of lymphedema, it gives not enough information about the severity of the lymphedema. a more detailed and comprehensive classification system applicable for primary and secondary lymphedema and considering multiple edema characteristics, remains to be formulated. the researchers objective in this study is to develop a diagnostic set, including a 'severity score', for patients with lll.


Eligibility criteria:
inclusion criteria: patient group * unilateral or bilateral, primary or secondary lll * objective diagnosis of lymphedema: ≥ 5% volume difference between both legs or ≥ 2 minor/ 1 major criteria on lymphoscintigraphy or presence of icg dermal backflow * age ≥ 18 years * able to read, understand and speak dutch healthy controls - age, gender \& bmi-matched healthy controls exclusion criteria: * pregnant participants * presence of chronic venous insufficiency c4, c5, c6; deep venous thrombosis; post-thrombotic syndrome * presence of skin infections of wounds at the level of the lower limbs at the moment of inclusion

Keywords: severity score diagnostic set
prevention and management of food allergies

Conditions: Empathy; Food Allergy

Summary: this pilot study will test the use of visual cues to engage food service workers in protecting patrons with food allergies. food service workers from philadelphia quick-service restaurants were recruited to participate in a survey of attitudes that includes an embedded randomized experiment testing an experimental cue (photograph of an allergic child) to increase workers' engagement and empathy.

aim: investigators pilot-tested a novel strategy to engage food service workers, by using a visual cue to increase the workers empathy for and desire to protect the patrons health and safety. why intervene with food service workers? both food allergies and allergenic foods are common, as is eating, making accidental ingestion of allergenic foods almost inevitable. risks may be particularly pronounced in out-of-home contexts (restaurants, school cafeterias, etc.), where the food allergic person must rely on service workers to assure their safety. therefore, food service workers are important partners in the prevention of adverse events. design: within the context of a survey of food service workers, investigators embedded a randomized experiment. in this experiment, investigators randomly assigned survey participants to one of two conditions: a personalized vs. depersonalized chef card. depersonalized chef cards included simple written instructions regarding the patron's specific food allergies, including explicit guidance regarding foods to be avoided and information regarding the seriousness of the allergy. personalized chef cards included identical written instructions and information, as well as a photograph of a patron with food allergies. hypothesis: service workers exposed to the personalized (compared to depersonalized) chef cards will demonstrate greater empathy, sympathy, willingness to help, and vigilance regarding food allergies and their management.

Eligibility criteria:
inclusion criteria: * employed at a quick-service restaurant * speaks english exclusion criteria: * work at a table-only establishment
phase i/ii trial of redox regulation in patients with relapsed or refractory cd20+ nhl

Conditions: Non-Hodgkin's Lymphoma (NHL)

Summary: monoclonal antibodies such as rituximab and yttrium y 90 ibritumomab tiuxetan can locate cancer cells and either kill them or deliver radioactive cancer-killing substances to them without harming normal cells. motexafin gadolinium may increase the effectiveness of yttrium y 90 ibritumomab tiuxetan by making the cancer cells more sensitive to the drug. this phase i/ii trial is studying the side effects and best dose of motexafin gadolinium when administered with rituximab and yttrium y 90 ibritumomab tiuxetan and to see how well they work in treating patients with stage ii, stage iii, or stage iv relapsed or refractory non-hodgkin's lymphoma.

this is a phase i, dose-escalation study of motexafin gadolinium followed by a phase ii study. patients are stratified according to extent of lymphomatous involvement (≤ 5% vs \> 5 but ≤ 24% of cellular elements). cohorts of 3-6 patients in each stratum receive escalating doses of motexafin gadolinium until the maximum tolerated dose (mtd) is determined. the mtd is defined as the dose at which 2 of 6 patients experience dose-limiting toxicity (dlt) or the dose preceding that at which 2 of 3 or 3 of 6 patients experience dlt. * once the mtd is determined, additional patients are treated at that dose level as in phase i. patients are followed weekly for 3 months and then monthly for 5 years.

Eligibility criteria:
disease characteristics: * histologically confirmed diagnosis of one of the following: * low-grade or follicular b-cell non-hodgkin's lymphoma (nhl) * the following histologies are eligible: * small lymphocytic lymphoma * lymphoplasmacytoid lymphoma * follicular center grades 1, 2, or 3 lymphoma * extranodal marginal zone b-cell lymphoma of mucosa-associated lymphoid tissue type * nodal marginal zone b-cell lymphoma * relapsed or refractory after 2 prior treatment regimens or 1 anthracycline regimen * diffuse large b-cell nhl or mantle cell lymphoma in first or second relapse * transformed nhl, defined as low-grade nhl transformed to diffuse large b-cell lymphoma, with no more than 1 relapse since transformation age 18 and over recovered from prior immunotherapy life expectancy at least 3 months recovered from prior chemotherapy * more than 4 weeks since prior major surgery and recovered * more than 4 weeks since prior anticancer therapy recovered from prior radiotherapy exclusion criteria: no major bleeding within the past 4 weeks no uncontrolled hypertension no stroke within the past 4 weeks * no active infection * no other active nonmalignant disease * no known g6pd deficiency * no history of porphyria * no other condition that would preclude study participation * no human anti-mouse antibodies * no known history of hiv * not pregnant or nursing * negative pregnancy test * fertile patients must use effective contraception * no prior radioimmunoconjugate therapy * no prior exposure to murine antibodies other than rituximab * more than 4 weeks since prior rituximab * no history of failed stem cell collection
mutation p.ile112thr : discrepancy between factor ix level and bleeding phenotype

Conditions: Hemophilia B

Summary: it appears that the mutation p.ile112thr in the factor ix gene confers a discrepancy between mild factor ix level and severe bleeding phenotype. databases and litterature analysis are poor on this matter. the goal of this study is to compile bleeding phenotype in patients with this specific mutation to prove the clinico-biological discordance in order to improve patient care and follow-up.


Eligibility criteria:
inclusion criteria: * hemophilia b with p.ile112thr mutation on factor ix gene exclusion criteria: none
study to evaluate the effect of gbt440 on tcd in pediatrics with sickle cell disease

Conditions: Sickle Cell Disease

Summary: this study is a phase 3, randomized, double-blind, placebo-controlled study of voxelotor in pediatric participants, aged ≥ 2 to \< 15 years old, with sickle cell disease. the primary objective is to evaluate the effect of voxelotor on the tcd (transcranial doppler ultrasound) measurements in scd participants in this age range.

this study is a phase 3, randomized, double-blind, placebo-controlled study of voxelotor in pediatric participants, aged ≥ 2 to \< 15 years old, with sickle cell disease. the study will be conducted at approximately 50 international clinical sites, and will enroll approximately 224 participants. participants will be randomized in a 1:1 ratio to receive voxelotor or placebo. all participants younger than 12 years of age and randomized to voxelotor will receive a dose based on their body weight, to provide exposure corresponding to the adult dose of 1500 mg/day.

Eligibility criteria:
inclusion criteria: 1. male or female participants with sickle cell anemia (sca) hbss, hbsβ0 thalassemia genotype 2. tcd time averaged maximum of the mean velocity (tammv) arterial cerebral blood flow ≥ 170 to \< 200cm/sec during the screening period 3. hb ≥ 5.5 and ≤ 10.5 g/dl during screening 4. for participants taking hu, the dose of hu (mg/kg) must be stable for at least 90 days prior to signing the informed consent form (icf) and/or assent form, and with no anticipated need for dose adjustments (other than weight based) or for initiation of hu for non-chronic use during the study, in the opinion of the investigator 5. written informed parental/guardian consent and participant assent (where applicable) has been obtained per irb/ec policy and requirements, consistent with ich guidelines. exclusion criteria: 1. body weight \< 10kg at the screening visit 2. hospitalization for voc or acute chest syndrome (acs) within the 14 days prior to execution of informed consent/assent 3. more than 10 vocs within the past 12 months that required hospitalization, emergency room, or clinic visit 4. stroke resulting in focal neurological deficit; previous silent infarcts are permitted. 5. known history or findings suggestive of significant cerebral vasculopathy 6. history of seizure disorder 7. has been treated with erythropoietin or other hematopoietic growth factors within 28 days of signing informed consent/assent or if, in the opinion of the investigator, there is an anticipated need for such agents during the study 8. rbc transfusion therapy (also termed chronic, prophylactic, or preventative transfusion) or has received an rbc transfusion or exchange transfusion for any reason within 90 days of signing the informed consent/assent

Keywords: sickle cell disease transcranial doppler ultrasound (tcd)
hepatic arterial infusion chemotherapy (haic) combined with durvalumab and lenvatinib in patients with locally advanced or metastatic intrahepatic cholangiocarcinoma: a phase 2 study(haic-quad trial)

Conditions: Intrahepatic Cholangiocarcinoma (Icc); HAIC; Durvalumab

Summary: at present, the first-line treatment for patients with advanced unresectable intrahepatic cholangiocarcinoma is mainly systemic treatment, but the improvement in efficacy is limited and is not enough to meet the current clinical treatment needs. hepatic artery infusion chemotherapy (haic) has the advantages of increasing local drug concentration and reducing toxic side effects compared to systemic intravenous chemotherapy. in order to enable patients with advanced intrahepatic cholangiocarcinoma to obtain better treatment effects, this study plans to explore haic combined with durvalumab and lenvatinib as the first-line treatment for patients with locally advanced or metastatic icc, in order to provide a better treatment choice for their comprehensive treatment.


Eligibility criteria:
inclusion criteria: 1. histologically confirmed intrahepatic cholangiocarcinoma, with a preliminary diagnosis of unresectable or metastatic disease and no previous systemic treatment. anatomical factors: ① patients with invasion of the portal vein, hepatic vein or main bile duct, who cannot undergo resection and reconstruction; ② patients with decompensated cirrhosis or severe portal hypertension, and the residual liver flr does not meet the safe liver resection decision-making system biological factors: ① multiple tumors in the left and right livers; ② metastasis to distant lymph nodes such as the para-aorta or distant organ metastasis 2. disease recurrence \> 6 months after radical surgery; if adjuvant therapy is given after surgery, patients \> 6 months after completion of adjuvant therapy (chemotherapy and/or radiotherapy) are eligible for inclusion. 3. who/ecog ps of 0 or 1 4. there was at least 1 target lesion (tl) that met the recist 1.1 criteria exclusion criteria: 1. patients who have received systemic treatment in the past. 2. patients with severe liver dysfunction (child-pugh c grade), or significant jaundice, hepatic encephalopathy, refractory ascites, or hepatorenal syndrome. 3. patients with severe and uncorrectable coagulation dysfunction. 4. patients with active hepatitis or severe infection who cannot be treated simultaneously. 5. patients with cachexia or multiple organ failure.

Keywords: locally advanced or metastatic intrahepatic cholangiocarcinoma durvalumab lenvatinib haic
effectiveness and safety study of pentosan polysulfate sodium for the treatment of interstitial cystitis

Conditions: Interstitial Cystitis

Summary: the purpose of this study is to evaluate the safety and effectiveness of pentosan polysulfate sodium 100 mg once a day, pentosan polysulfate sodium 100 mg three times a day, and placebo for 24 weeks for the relief of bladder pain or discomfort associated with interstitial cystitis.

the purpose of this multi-center, double-blind (neither the patient nor the physician knows whether drug or placebo is being taken, or at what dosage), randomized (patients are assigned different treatments based on chance), parallel group trial is to evaluate the effectiveness and safety of two doses of pentosan polysulfate sodium (100 mg once a day and 100 mg three times a day) versus placebo for 24 weeks for the relief of bladder pain or discomfort associated with interstitial cystitis. the hypothesis of the study is that there is no treatment difference in the proportion of responders at study endpoint (week 24). effectiveness will be assessed based on the reduction in the o'leary-sant interstitial cystitis symptom index (icsi) total score. safety assessments include vital signs, laboratory tests, adverse events and physical exams. patients will receive one of the following study treatments by mouth each day for 24 weeks: pentosan polysulfate sodium 100 mg once a day group - one pentosan polysulfate sodium 100 mg capsule in the morning, and one matching placebo capsule in the afternoon and evening; pentosan polysulfate sodium 100 mg capsule three times a day group - one pentosan polysulfate sodium 100 mg capsule in the morning, afternoon and evening; placebo group - one placebo capsule in the morning, afternoon and evening

Eligibility criteria:
inclusion criteria: * must have a total score of 8 or greater on the o'leary-sant interstitial cystitis symptom index (icsi) and a score of \> 0 on each of the 4 questions on the icsi * must have experienced bladder pain, urinary urgency and urinary frequency, each not related to a urinary tract infection, for at least 6 months prior to entry into the study * must have averaged \>= 10 voids per day (\>=30 voids over 3 consecutive days) and averaged \>= 1 void at night * urine culture showing no evidence of urinary tract infection * urine cytology showing no evidence of neoplastic cells exclusion criteria: * scheduled for or use of intravesical therapy (eg, bladder distention, dimethyl sulfoxide) during or within 4 weeks prior to the study * patients who have had cytoscopic evaluation within 4 weeks prior to the study * patients who are currently (within last month) receiving other medications that may affect symptoms of interstitial cystitis (ie, antidepressants, antihistamines, antispasmodics, anticholinergics) * patients who are chronic users of schedule ii narcotics or who are using any scheduled narcotics at the time of study entry * patients taking coumadin, anticoagulants, heparin, or thrombolytic agents such as tissue plasminogen activator and streptokinase

Keywords: interstitial cystitis urinary bladder pain
intralesional acyclovir versus cryotherapy in the treatment of plantar warts. a randomized controlled trial.

Conditions: Plantar Wart

Summary: the goal of this prospective randomized controlled study is to study the safety and efficacy of intralesional acyclovir compared to cryotherapy in plantar warts. the main questions needed to be answered are: 1. is intralesional acyclovir safe for plantar warts? 2. is intralesional acyclovir more efficient in treating plantar warts compared to cryotherapy?


Eligibility criteria:
inclusion criteria: * patients aged 18 years or older, of both genders, with plantar warts exclusion criteria: * patients on systemic treatment for warts eg. acitretin, acyclovir * hypersensitivity to acyclovir * previous treatment to the same wart during the last 3 months * immunocompromised patients (as hiv, steroid intake, uncontrolled diabetes, etc.) * pregnant and breastfeeding females * cognitively impaired patients
dupilumab in the treatment of severe uncontrolled crswnp: a multicentre observational real-life study (dupireal)

Conditions: Chronic Rhinosinusitis With Nasal Polyps

Summary: chronic rhinosinusitis with nasal polyps (crswnp) is a sino-nasal chronic inflammatory disease that strongly affects patients' quality of life, especially in difficult-to-treat cases. in severe uncontrolled crswnp, the inflammation is mostly driven by a type 2 inflammatory pathway and its management has been rapidly changing during the last 2 years due to dupilumab approval. it is a fully human monoclonal antibody that binds the alpha subunit of il-4 receptors (il-4rα type 1 and type 2) to inhibit il-4 and il-13 signaling. so far, randomized clinical trials have assessed efficacy and safety of dupilumab in a large number of patients, whereas evidences in real life clinical practice are limited to few monocentric series. herewith, the investigators present a multicenter, observational nationwide retrospective real-life study with the aim to confirm the effectiveness and the safety of dupilumab over the first year of treatment in a real life setting. the primary objective is to evaluate the volumetric reduction of polyps by measuring the variation of total nasal polyp endoscopic score (nps). the secondary objectives are: * the evaluation of changes in nasal symptoms, olfactory function and nasal obstruction * the assessment of the patients' quality of life * the recording of major and minor complications * the evaluation of the response to the therapy, according to epos2020 criteria and euforea2021 * the assessment of efficacy based on concomitant disease (asthma and asa triad) * the evaluation of potential predictors of clinical response to the therapy


Eligibility criteria:
inclusion criteria: * confirmed diagnosis of diffuse crswnp by endoscopy and ct scan performed at least 6 months prior of the therapy; * severe disease stage defined by nps ≥5 or snot-22 ≥50; * inadequate symptom control with incs therapy; * failure or intolerance of previous medical treatments (at least 2 cycles of systemic corticosteroid in the last year), and/or failure of previous surgical treatment through nasal endoscopic surgery (ess), with postoperative complications or no clinical benefit exclusion criteria: * pregnant women; * immunosuppressive therapy; * patients undergoing radio-chemotherapy treatments for cancer in the 12 months before the starting of therapy; * concomitant long-term corticosteroid therapy for chronic autoimmune disorders